Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2019 /
ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia

29th Mar - 3rd Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.04.19
Views: 1730

Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA

Prof Alexander Perl speaks to ecancer at the 2019 American Association for Cancer Research (AACR) meeting about results from the ADMIRAL trial which looked at the use of gilteritinib as treatment for patients with elapsed or refractory acute myeloid leukaemia (AML) in comparison with standard chemotherapy regimens.

He explains that patients with relapsed or refractory FLT3-mutated AML have historically had a very poor prognosis, with chemotherapy treatment generally yielding low remission rates.

Prof Perl reports that the FLT3-targeted drug gilteritinib was compared with the best available current chemotherapy treatment, with response doubled in almost every metric looked at (in favour of gilteritinib).

Read more about this research here.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation